Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic XXXX .

@entity5 @entity1 @entity984 @entity14
BACKGROUND: The detection of circulating DNA is considered a promising strategy in @entity5 @entity1 . Digital PCR has emerged as a sensitive method able to quantify both circulating free and @entity5 DNA. AIM: The aim of this study was to prospectively evaluate the clinical value of a chip-based digital PCR for the detection of circulating DNA. METHODS: Digital PCR was used in 34 metastatic @entity14 @entity1 to detect and quantify circulating free and @entity5 DNA based on @entity984 mutational status. Clinical outcomes were analyzed according to circulating DNA measurements. RESULTS: Digital PCR yielded a detection rate of 69% for circulating @entity5 DNA. The median concentrations of circulating free and @entity5 DNA were 20 and 6.8ng/mL, respectively, with significant correlation between both biomarkers (p<0.001). Median overall survival was 4.8 months in @entity1 with high circulating free DNA (>75% quartile) versus not reached in @entity1 with a low level (<25% quartile) (p=0.029). Moreover, median overall survival was significantly decreased in @entity1 with detectable circulating @entity5 DNA compared to those without (respectively 11.8 months versus not reached, p=0.04). CONCLUSIONS: Chip-based digital PCR is a simple and non-invasive method allowing the efficient detection of circulating DNA. Our results highlight that levels of these circulating markers may have a potential prognostic value.
